clevudine Report issue

Small molecule Experimental
AACT ChEMBL Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Clevudine (INN) is an antiviral drug for the treatment of hepatitis B (HBV). It is already approved for HBV in South Korea and the Philippines. It is marketed by Bukwang Pharmaceuticals in South Korea under the tradenames Levovir and Revovir.   Wikipedia

Chemistry

  • SMILES: Cc1cn([C@H]2O[C@@H](CO)[C@H](O)[C@H]2F)c(=O)[nH]c1=O
  • InChIKey: GBBJCSTXCAQSSJ-XQXXSGGOSA-N
  • Mol. Mass: 260.22
  • ALogP: -1.57
  • ChEMBL Molecule:
    clevudine  
More Chemistry

Pharmacology

Alternative names

1-(2-fluoro-2-deoxy-beta-arabinofuranosyl)thymine | 1-(2-fluoro-2-deoxy-beta-d-arabinofuranosyl)thymine | 1-(2-fluoro-5-methyl-beta,l-arabinofuranosyl)uracil | 2,4(1h,3h)-pyrimidinedione, 1-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)-5-methyl- | 2'-deoxy-2'-fluoroarabinofuranosylthymine | 2'-fluoro-1-beta-arabinofuranosyl-5-methyluracil | 2'-fluoro-5-methyl-1-beta-arabinosyluracil | 2'-fluoro-5-methyl-1-beta-d-arabinofuranosyluracil | 2'-fluoro-5-methylarabinosyluracil | 2'-fluoro-5-methylarabinosyluracil, 2-(14)c-labeled | 5-methyl-2'-fluoroarauracil | clevudine | d-fmau | fmau | levovir | l-fmau

Organizations (18)

Research & Development (18)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (1)


 

Hepatitis B

Experimental Indications - Clinical Trial Phases 1-4 (6)


 

Carcinoma, Hepatocellular (Phase 4)

COVID-19 (Phase 2)

Healthy Volunteers (Phase 1)

Hepatitis B (Phase 4)

Hepatitis B, Chronic (Phase 4)

Hepatitis, Chronic (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 30
  • # of Trial Organizations: 18

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue